Genetic determinants of clinical outcome and treatment response in chronic hepatitis C
Grant number: 567057 | Funding period: 2009 - 2012
Chronic hepatitis C infection (CHC) causes liver failure, liver cancer and death. The treatment response rate is poor. Understanding of the factors that increase an individual’s risk of developing serious liver disease, or that lead to treatment failure, is limited. This project, the first of its kind, will involve screening 1600 CHC patients for genes that are associated with disease outcome and treatment response, to identify novel targets for drug and vaccine development
Related publications (4)
IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha
Jacinta A Holmes, Nguyen Tin, Dilip Ratnam, Neel M Heerasing, Jane V Tehan, Sara Bonanzinga, Anouk Dev, Sally Bell, Stephen Pianko, Robert Chen, Kumar Visvanathan, Rachel Hammond, David Iser, Ferry Rusli, William Sievert, Paul V Desmond, D Scott Bowden, Alexander J Thompson
BACKGROUND AND AIM: IL28B genotype predicts response to pegylated interferon (peg-IFN)-based therapy in chronic hepatitis C. Howev..
Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner
Paul J Clark, Alexander J Thompson, David M Vock, Lisa E Kratz, Adviye A Tolun, Andrew J Muir, John G McHutchison, Mani Subramanian, David M Millington, Richard I Kelley, Keyur Patel
UNLABELLED: Hepatitis C virus (HCV) subverts host cholesterol metabolism for key processes in its lifecycle. How this interference..